Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double‐blind, placebo‐controlled study
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: To conduct a robust, double‐blind, placebo‐controlled study examining the effects of tumor necrosis factor (TNF) modulation on concentrations of traditional and novel cardiovascular disease risk factors in patients with an inflammatory condition. Methods: In this double‐blind study, 127 patients with psoriatic arthritis (PsA) and active psoriasis were randomized to 1 of 3 treatment arms (placebo, onercept 50 mg, or onercept 100 mg for 12 weeks). Traditional and novel biochemical risk factors were evaluated at baseline and at the end of the treatment period. Results: At baseline, an elevated C‐reactive protein (CRP) level correlated positively with lipoprotein(a) (Lp[a]), intercellular adhesion molecule 1, interleukin‐6, and homocysteine levels but was inversely correlated with concentrations of all other lipid moieties and sex hormone binding globulin (SHBG). Onercept at a dose of 100 mg induced significant (P ≤ 0.002) reductions in the levels of CRP (−14.0 versus 6.5 mg/liter with placebo), Lp(a) (−3.11 versus 1.52 mg/dl with placebo), and homocysteine (−1.72 versus 0.34 μmoles/liter with placebo) and an increase in the SHBG concentration (4.3 versus −1.3 mmoles/liter with placebo). The 100‐mg dose of onercept was also associated with significant (P < 0.05) increases in the level of circulating apolipoprotein AI (Apo A‐I) (4.0 versus −5.6 mg/dl with placebo); however, levels of Apo B (6.3 versus −0.4 mg/dl with placebo) and triglycerides (0.09 versus 0.04 mmoles/liter) were also increased. Conclusion: This study is the first to demonstrate that targeting the TNF pathway can significantly decrease Lp(a) and homocysteine levels and elevate Apo A‐I and SHBG concentrations. These data support an important precursor role for high‐grade inflammation in modulating these putative risk parameters. However, TNF blockade–induced increases in triglyceride and Apo B levels were unexpected and suggest that it is not possible, on the basis of biochemical changes in isolation, to suggest that cardioprotection would necessarily follow; rather, direct measures of atherosclerotic progression with TNF blockade (e.g., using carotid ultrasound) would be better.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Risk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060900 · Cited by 1,729
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
Bønaa, K. H., Njølstad, I., Ueland, P. M., Schirmer, H., Tverdal, A., Steigen, T., Wang, H., Nordrehaug, J. E., Arnesen, E., & Rasmussen, K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055227 · Cited by 1,442
Mann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Inflammatory pathways and insulin action
Hotamisligil, G. S. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802502 · Cited by 717
WALLDIUS, G., & JUNGNER, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01643.x · Cited by 583
Association of Bioavailable, Free, and Total Testosterone With Insulin Resistance
Tsai, E. C., Matsumoto, A. M., Fujimoto, W. Y., & Boyko, E. J. (2004) · Diabetes Care · doi:10.2337/diacare.27.4.861 · Cited by 307
Cited by
Smolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399
Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104
Davidovici, B. B., Sattar, N., Jörg, P. C., Puig, L., Emery, P., Barker, J. N., van de Kerkhof, P., Ståhle, M., Nestle, F. O., Girolomoni, G., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.103 · Cited by 711
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Novel insights in SHBG regulation and clinical implications
Simó, R., Sáez-López, C., Barbosa-Desongles, A., Hernández, C., & Selva, D. M. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.05.001 · Cited by 335
McInnes, I. B., Thompson, L., Giles, J. T., Bathon, J. M., Salmon, J. E., Beaulieu, A. D., Codding, C. E., Carlson, T. H., Delles, C., Lee, J. S., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204345 · Cited by 324
Self-citationChoy, E., Ganeshalingam, K., Semb, A. G., Szekanecz, Z., & Nurmohamed, M. (2014) · Rheumatology · doi:10.1093/rheumatology/keu224 · Cited by 303
Role for TNF in atherosclerosis? Lessons from autoimmune disease
McKellar, G. E., McCarey, D. W., Sattar, N., & McInnes, I. B. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.57 · Cited by 295
Self-citationChoy, E., & Sattar, N. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101964 · Cited by 293
Self-citationCardiovascular comorbidities in patients with psoriatic arthritis: a systematic review
Jamnitski, A., Symmons, D., Peters, M. J. L., Sattar, N., MciInnes, I., & Nurmohamed, M. T. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201194 · Cited by 276
Self-citationChanges in lipid levels with inflammation and therapy in RA: a maturing paradigm
Robertson, J., Peters, M. J., McInnes, I. B., & Sattar, N. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.91 · Cited by 264
Self-citationTam, L.-S., Tomlinson, B., Chu, T. T.-W., Li, M., Leung, Y.-Y., Kwok, L.-W., Li, T. K., Yu, T., Zhu, Y.-E., Wong, K.-C., et al. (2008) · Rheumatology · doi:10.1093/rheumatology/ken090 · Cited by 257
Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?
Sattar, N., Wannamethee, S. G., & Forouhi, N. G. (2008) · Diabetologia · doi:10.1007/s00125-008-0954-7 · Cited by 143
Self-citationGabay, C., McInnes, I. B., Kavanaugh, A., Tuckwell, K., Klearman, M., Pulley, J., & Sattar, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207872 · Cited by 140
Self-citationLongitudinal Changes in Sex Hormone–Binding Globulin in Men With HIV
Pena Dias, J., Haberlen, S. A., Dobs, A. S., Lake, J. E., Palella, F. J., Kingsley, L. A., Price, J. C., Basaria, S., Varadhan, R., Margolick, J. B., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002723 · Cited by 11
Metadata
- Authors
- Sattar, N., Crompton, P., Cherry, L., Kane, D., Lowe, G., & McInnes, I. B.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-02-27
- Volume
- 56
- Issue
- 3
- Pages
- 831-839
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2026082319
- Cited by
- 120
- References
- 9
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.